FMP

FMP

Enter

TNG.PA - Transgene SA

Financial Summary of Transgene SA(TNG.PA), Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and

photo-url-https://financialmodelingprep.com/image-stock/TNG.PA.png

Transgene SA

TNG.PA

EURONEXT

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

1.33 EUR

-0.05 (-3.75%)

About

ceo

Dr. Alessandro Riva M.D.

sector

Healthcare

industry

Biotechnology

website

https://www.transgene.fr

exchange

EURONEXT

Description

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, whic...

CIK

N/A

ISIN

FR0005175080

CUSIP

N/A

Address

400, Boulevard Gonthier d’Ande...

Phone

33 3 88 27 91 00

Country

FR

Employee

143

IPO Date

Apr 12, 2000

Summary

CIK

-

Exchange

EURONEXT

Industry

Biotechnology

Sector

Healthcare

CUSIP

-

ISIN

FR0005175080

Country

FR

Price

1.33

Beta

0.72

Volume Avg.

36.96k

Market Cap

133.93M

Shares

-

52-Week

1.03-2.55

DCF

0.05

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-6.05

P/B

-

Website

https://www.transgene.fr

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest TNG.PA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep